Sheba Medical Center

Running trials

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Phase 2· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· Source

• Not yet recruiting

  Combination CurQD and Vedolizumab in Ulcerative Colitis

  NCT07665294· Phase 4· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes

  NCT07828106· Source

• Recruiting

  Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)

  NCT07227805· Source

• Recruiting

  IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome

  NCT07707635· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Source

• Recruiting

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Phase 2/3· Source

• Not yet recruiting

  A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

  NCT07503353· Phase 1/2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Source

• Recruiting

  A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

  NCT07609914· Phase 4· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Source

• Recruiting

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· Phase 2/3· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Source

• Recruiting

  A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

  NCT07286149· Phase 1/2· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Source

• Recruiting

  Arm Position and Blood Pressure Measurement Accuracy During Pregnancy

  NCT07405723· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

  NCT07440225· Phase 2/3· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Not yet recruiting

  Mitochondrial Function After Ketamine

  NCT07399756· Source

• Recruiting

  A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

  NCT07135466· Phase 1/2· Source

• Recruiting

  Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

  NCT07919015· Source

• Recruiting

  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

  NCT07227597· Phase 1/2· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Source

• Recruiting

  MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC

  NCT07327021· Phase 2· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Source

• Recruiting

  Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

  NCT07293923· Source

• Recruiting

  Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure

  NCT07881666· Phase 1· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Phase 3· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer25 recruiting
• Childhood cancers12 recruiting
• Bladder cancer8 recruiting
• Colorectal cancer7 recruiting
• Crohn's disease7 recruiting
• Multiple myeloma7 recruiting
• Ovarian cancer7 recruiting
• Metastatic breast cancer6 recruiting
• Triple-negative breast cancer6 recruiting
• Obesity5 recruiting
• Ulcerative colitis5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Gastric and esophageal cancer4 recruiting
• Melanoma4 recruiting
• Pancreatic cancer4 recruiting
• Prostate cancer4 recruiting
• Type 1 diabetes4 recruiting
• Bipolar disorder3 recruiting
• Haemophilia3 recruiting
• Kidney cancer3 recruiting
• Type 2 diabetes3 recruiting
• Amyloidosis2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Depression2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometrial cancer2 recruiting
• Follicular lymphoma2 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lupus (SLE)2 recruiting
• Schizophrenia2 recruiting
• Stroke2 recruiting
• Acute myeloid leukemia1 recruiting
• Alzheimer disease1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Epilepsy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Glaucoma1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Macular degeneration1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Parkinson disease1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

  NCT07084831· Phase 3· Source

• Completed

  Time Course of Clozapine-associated Agranulocytosis Over 19 Years

  NCT07913529· Source

• Completed

  Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

  NCT07240831· Source

• Completed

  GV101 in Healthy Obese Participants

  NCT06979505· Phase 2· Source

• Terminated

  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Phase 3· Source

• Completed

  A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

  NCT06894771· Phase 1· Source

• Completed

  Description of Patients With Type 1 Diabetes Treated With Teplizumab

  NCT06892002· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Source

• Completed

  The Yield of Artificial Intelligence (GI Genius) in Lynch Syndrome - A Randomized Tandem-colonoscopy Trial

  NCT06654128· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Completed

  Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus

  NCT06236256· Source

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Source

• Completed

  Virtual Reality for Anxiety and Pain Management in Transvaginal Ultrasound for Endometriosis

  NCT07328061· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Completed

  Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

  NCT06045507· Phase 2· Source

• Completed

  Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

  NCT05304546· Phase 2· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

  NCT05952856· Phase 3· Source

• Completed

  A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Phase 2· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Source

• Terminated

  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

  NCT05540665· Phase 2· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Source

• Completed

  To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

  NCT05483907· Phase 2· Source

• Completed

  A Study of Vedolizumab in Adults With Crohn's Disease (CD)

  NCT05192863· Source

• Completed

  A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

  NCT05551741· Phase 1· Source

• Completed

  Evaluating a Telemedicine-based Intensive Treatment Program for Children and Adolescents With Obesity

  NCT05700409· Source

• Terminated

  A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

  NCT06217146· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  Evaluation in STEMI Patients Using FDY-5301

  NCT04837001· Phase 3· Source

• Recruiting

  Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  NCT05219617· Phase 3· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Source

• Completed

  Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

  NCT05199337· Phase 1/2· Source

• Completed

  A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

  NCT05081557· Source

• Completed

  Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma

  NCT05078853· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· Phase 3· Source

• Completed

  Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

  NCT04517669· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Source

• Completed

  A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

  NCT04731467· Phase 1/2· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Phase 1· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Phase 1· Source

• Completed

  Evaluation of the Safety and Performance of Magneto Microcatheter

  NCT04466033· Source

• Terminated

  Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

  NCT04153175· Phase 2· Source

Trial sites

• Ella Institute - Sheba Medical Center1 trial
• Endometriosis Center, Sheba Medical Center1 trial
• Joseph Sagol Neuroscience center, Sheba Medical Center1 trial
• Jusidman Cancer Center, Sheba Medical Center1 trial
• Movement Disorders Institute, Sheba Medical Center1 trial
• Sheba medical center195 trials
• Sheba Medical Center - Cancer Center (Site 0002)1 trial
• Sheba Medical Center; Center Israel1 trial
• Sheba Medical Center /ID# 1459651 trial
• Sheba Medical Center /ID# 2025321 trial
• Sheba Medical Center /ID# 2074681 trial
• Sheba Medical Center /ID# 2074741 trial
• Sheba Medical Center /ID# 2449051 trial
• Sheba Medical Center - Oncology Division (Site 1501)1 trial
• Sheba Medical Center - Oncology Division (Site 3501)1 trial
• Sheba Medical Center - PPDS8 trials
• Sheba Medical Center - Sheba Fund for Health Services and Research1 trial
• Sheba Medical Center (Site 0001)1 trial
• Sheba Medical Center (Site 0010)1 trial
• Sheba Medical Center (Site 0070)3 trials
• Sheba Medical Center (Site 0180)1 trial
• Sheba Medical Center (Site 0200)2 trials
• Sheba Medical Center (Site 0220)2 trials
• Sheba Medical Center (Site 0300)1 trial
• Sheba Medical Center (Site 0361)1 trial
• Sheba Medical center (Site 0387)1 trial
• Sheba Medical Center (Site 0401)1 trial
• Sheba Medical Center (Site 0428)1 trial
• Sheba Medical Center (Site 0460)1 trial
• Sheba Medical Center (Site 0551)1 trial
• Sheba Medical Center (Site 0601)3 trials
• Sheba Medical Center (Site 0603)1 trial
• Sheba Medical Center (Site 0677)1 trial
• Sheba Medical Center (Site 0702)1 trial
• Sheba Medical Center (Site 0801)3 trials
• Sheba Medical Center (Site 0802)1 trial
• Sheba Medical Center (Site 0803)1 trial
• Sheba Medical Center (Site 0827)1 trial
• Sheba Medical Center (Site 0844)1 trial
• Sheba Medical Center (Site 0902)1 trial
• Sheba Medical Center (Site 1000)1 trial
• Sheba Medical Center (Site 1100)1 trial
• Sheba Medical Center (Site 1200)1 trial
• Sheba Medical Center (Site 1254)1 trial
• Sheba Medical Center (Site 1300)1 trial
• Sheba Medical Center (Site 1301)1 trial
• Sheba Medical Center (Site 1400)1 trial
• Sheba Medical Center (Site 1401)2 trials
• Sheba Medical Center (Site 1407)1 trial
• Sheba Medical Center (Site 1421)1 trial
• Sheba Medical Center (Site 1450)1 trial
• Sheba Medical Center (Site 1601)1 trial
• Sheba Medical Center (Site 1602)2 trials
• Sheba Medical Center (Site 1675)1 trial
• Sheba Medical Center (Site 1700)1 trial
• Sheba Medical Center (Site 1701)1 trial
• Sheba Medical Center (Site 1708)2 trials
• Sheba Medical Center (Site 1733)1 trial
• Sheba Medical Center (Site 2001)2 trials
• Sheba Medical Center (Site 2101)1 trial
• Sheba Medical Center (Site 2200)1 trial
• Sheba Medical Center (Site 2504)1 trial
• Sheba Medical Center (Site 3000)1 trial
• Sheba Medical Center (Site 3201)1 trial
• Sheba Medical Center (Site 3302)1 trial
• Sheba Medical Center (Site 3675)1 trial
• Sheba Medical Center (Site 3701)1 trial
• Sheba Medical Center (Site 4401)1 trial
• Sheba Medical Center (Site 4605)1 trial
• Sheba Medical Center (Site 4675)1 trial
• Sheba Medical Center (Site 5501)1 trial
• Sheba Medical Center (Site 707)1 trial
• Sheba Medical Center, Tel Hashomer11 trials
• Sheba Medical Center, Tel-HaShomer, Tel-Aviv University1 trial
• Sheba Medical Centre5 trials
• Sheba Medical Center3 trials
• Sheba medical center27 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease42 works · 11 trials
• Ulcerative colitis30 works · 10 trials
• Type 1 diabetes22 works · 9 trials
• Haemophilia17 works · 3 trials
• Neuroendocrine tumours12 works · 0 trials
• Hypertrophic cardiomyopathy9 works · 0 trials
• Primary biliary cholangitis4 works · 1 trial
• Follicular lymphoma4 works · 4 trials